Jeremy Kortmansky, MD
Associate Professor of Medicine (Medical Oncology)DownloadHi-Res Photo
Cards
Are You a Patient?
View this doctor's clinical profile on the Yale Medicine website for information about the services we offer and making an appointment.
View Doctor ProfileAdditional Titles
Associate Chief Medical Officer, Network Medical Services
Clinical Director, Division of GI Medical Oncology, Yale Cancer Center
Chief Network Officer, Smilow Cancer Hospital, Yale School of Medicine
Contact Info
Are You a Patient?
View this doctor's clinical profile on the Yale Medicine website for information about the services we offer and making an appointment.
View Doctor ProfileAdditional Titles
Associate Chief Medical Officer, Network Medical Services
Clinical Director, Division of GI Medical Oncology, Yale Cancer Center
Chief Network Officer, Smilow Cancer Hospital, Yale School of Medicine
Contact Info
Are You a Patient?
View this doctor's clinical profile on the Yale Medicine website for information about the services we offer and making an appointment.
View Doctor ProfileAdditional Titles
Associate Chief Medical Officer, Network Medical Services
Clinical Director, Division of GI Medical Oncology, Yale Cancer Center
Chief Network Officer, Smilow Cancer Hospital, Yale School of Medicine
Contact Info
About
Titles
Associate Professor of Medicine (Medical Oncology)
Associate Chief Medical Officer, Network Medical Services; Clinical Director, Division of GI Medical Oncology, Yale Cancer Center
Positions outside Yale
Chief Network Officer, Smilow Cancer Hospital, Yale School of Medicine
Biography
Dr. Kortmansky is an Associate Professor of Clinical Medicine (Medical Oncology) and the Chief Network Officer for the Smilow Cancer Hospital Network. He graduated from Northwestern University Medical School and completed his fellowship in Oncology at Memorial Sloan Kettering Cancer Center. Dr. Kortmansky has been caring for patients in Connecticut for more than 20 years, and has established a leading practice in gastrointestinal cancers.
Appointments
Medical Oncology
Associate Professor on TermPrimary
Other Departments & Organizations
- Center for Gastrointestinal Cancers
- Developmental Therapeutics
- Hepatic Arterial Infusion (HAI) Program
- Hyperthermic intraperitoneal chemotherapy (HIPEC) Program
- Internal Medicine
- Medical Oncology
- Oligometastatic Cancer Program
- Pancreatic Diseases Program
- Subset Medical Oncology Faculty
- Yale Cancer Center
- Yale Medicine
Education & Training
- Fellowship
- Memorial Sloan Kettering Cancer Center (2003)
- Residency
- Thomas Jefferson University Hospital (1999)
- MD
- Northwestern University Medical School, Medicine (1996)
Research
Overview
GI oncology
Medical Research Interests
Colorectal Neoplasms; Gastrointestinal Diseases; Pancreatic Neoplasms
Research at a Glance
Yale Co-Authors
Frequent collaborators of Jeremy Kortmansky's published research.
Publications Timeline
A big-picture view of Jeremy Kortmansky's research output by year.
Research Interests
Research topics Jeremy Kortmansky is interested in exploring.
Jill Lacy, MD
Michael Cecchini, MD
Kimberly L. Johung, MD, PhD
Neal Fischbach, MD
Henry S. Park, MD, MPH
Daniel Zelterman, PhD
62Publications
2,426Citations
Pancreatic Neoplasms
Colorectal Neoplasms
Publications
2024
A Phase 2 study of Savolitinib in Patients with MET Amplified Metastatic Colorectal Cancer
Jia J, Moyer A, Lowe M, Bolch E, Kortmansky J, Cho M, Lenz H, Kalyan A, Niedzwiecki D, Strickler J. A Phase 2 study of Savolitinib in Patients with MET Amplified Metastatic Colorectal Cancer. Journal Of Gastrointestinal Cancer 2024, 56: 29. PMID: 39652198, DOI: 10.1007/s12029-024-01156-x.Peer-Reviewed Original ResearchMeSH Keywords and ConceptsConceptsTreatment-emergent adverse eventsMetastatic colorectal cancerPhase 2 studyEpidermal growth factor receptorAnti-tumor activityStable diseaseProgressive diseaseChemotherapy refractory metastatic colorectal cancerOral small-molecule tyrosine kinase inhibitorColorectal cancerResistance to epidermal growth factor receptorSmall molecule tyrosine kinase inhibitorsRefractory metastatic colorectal cancerBest overall responseRAS wild-typeAdvanced solid tumorsBiomarker-selected patientsTyrosine kinase inhibitorsWild-typeGrowth factor receptorResultsFive patientsPrimary endpointSecondary endpointsSolid tumorsSavolitinibPerioperative Modified FOLFIRINOX for Resectable Pancreatic Cancer
Cecchini M, Salem R, Robert M, Czerniak S, Blaha O, Zelterman D, Rajaei M, Townsend J, Cai G, Chowdhury S, Yugawa D, Tseng R, Arbelaez C, Jiao J, Shroyer K, Thumar J, Kortmansky J, Zaheer W, Fischbach N, Persico J, Stein S, Khan S, Cha C, Billingsley K, Kunstman J, Johung K, Wiess C, Muzumdar M, Spickard E, Aushev V, Laliotis G, Jurdi A, Liu M, Escobar-Hoyos L, Lacy J. Perioperative Modified FOLFIRINOX for Resectable Pancreatic Cancer. JAMA Oncology 2024, 10: 1027-1035. PMID: 38900452, PMCID: PMC11190830, DOI: 10.1001/jamaoncol.2024.1575.Peer-Reviewed Original ResearchConceptsProgression-free survivalPancreatic ductal adenocarcinomaOverall survivalCtDNA levelsPhase 2 nonrandomized controlled trialAnalysis of circulating tumor DNAMedian progression-free survivalResectable pancreatic ductal adenocarcinomaControlled trialsAssess surgical candidacyBaseline ctDNA levelModified 5-fluorouracilResectable pancreatic cancerPancreatic protocol computed tomographyAssociated with recurrenceTumor molecular featuresAggressive malignant tumorKaplan-Meier estimatesRandomized clinical trialsStandard of careCtDNA-positivePreoperative cyclesNonrandomized controlled trialsUnresectable diseaseModified FOLFIRINOXA single arm phase 2 clinical trial of YIV-906 with neoadjuvant concurrent chemo-radiation therapy in patients with locally advanced rectal cancer
Verma N, Johung K, Kortmansky J, Zaheer W, Lacy J, Cecchini M, Stein S, Cheng Y, Lam W, Liu S, Reddy V, Hochster H, Higgins S. A single arm phase 2 clinical trial of YIV-906 with neoadjuvant concurrent chemo-radiation therapy in patients with locally advanced rectal cancer. Journal Of Gastrointestinal Oncology 2024, 15: 1050-1059. PMID: 38989411, PMCID: PMC11231844, DOI: 10.21037/jgo-24-23.Peer-Reviewed Original ResearchAltmetricCombining antivascular endothelial growth factor and anti-epidermal growth factor receptor antibodies: randomized phase II study of irinotecan and cetuximab with/without ramucirumab in second-line colorectal cancer (ECOG-ACRIN E7208)
Hochster H, Catalano P, Weitz M, Mitchell E, Cohen D, O’Dwyer P, Faller B, Kortmansky J, O’Hara M, Kricher S, Lacy J, Lenz H, Verma U, Benson A. Combining antivascular endothelial growth factor and anti-epidermal growth factor receptor antibodies: randomized phase II study of irinotecan and cetuximab with/without ramucirumab in second-line colorectal cancer (ECOG-ACRIN E7208). Journal Of The National Cancer Institute 2024, 116: 1487-1494. PMID: 38775718, PMCID: PMC11378308, DOI: 10.1093/jnci/djae114.Peer-Reviewed Original ResearchCitationsConceptsProgression-free survivalDisease-control ratePhase 3 trialColorectal cancerAnti-VEGFAnti-VEGFRAnti-EGFRKRAS-wild type colorectal cancerPhase II study of irinotecanKRAS wild-type colorectal cancerMedian progression-free survivalRandomized phase II studyKRAS wild-type tumorsWild-type colorectal cancerAnti-VEGFR antibodiesAnti-VEGF drugsTreated with ICSecond-line treatmentStudy of irinotecanWild-type tumorsAdvanced colorectal cancerPhase 2 studyAnti-EGFR antibodiesAnti-VEGF antibodyECOG PSPembrolizumab Plus Binimetinib With or Without Chemotherapy for MSS/pMMR Metastatic Colorectal Cancer: Outcomes From KEYNOTE-651 Cohorts A, C, and E
Chen E, Kavan P, Tehfe M, Kortmansky J, Sawyer M, Chiorean E, Lieu C, Polite B, Wong L, Fakih M, Spencer K, Chaves J, Li C, Leconte P, Adelberg D, Kim R. Pembrolizumab Plus Binimetinib With or Without Chemotherapy for MSS/pMMR Metastatic Colorectal Cancer: Outcomes From KEYNOTE-651 Cohorts A, C, and E. Clinical Colorectal Cancer 2024, 23: 183-193. PMID: 38653648, DOI: 10.1016/j.clcc.2024.03.002.Peer-Reviewed Original ResearchAltmetricConceptsObjective response rateMetastatic colorectal cancerCohort ACohort CCohort EDose escalationInvestigator-assessed objective response rateColorectal cancerResponse rateModified toxicity probability interval designDose reductionSafety findingsPrimary endpointPembrolizumabBinimetinibLeucovorinE. CONCLUSIONSChemotherapyPatientsCohortIrinotecanOxaliplatinCancerInterval designWeeksPembrolizumab Plus mFOLFOX7 or FOLFIRI for Microsatellite Stable/Mismatch Repair-Proficient Metastatic Colorectal Cancer: KEYNOTE-651 Cohorts B and D
Kim R, Tehfe M, Kavan P, Chaves J, Kortmansky J, Chen E, Lieu C, Wong L, Fakih M, Spencer K, Zhao Q, Predoiu R, Li C, Leconte P, Adelberg D, Chiorean E. Pembrolizumab Plus mFOLFOX7 or FOLFIRI for Microsatellite Stable/Mismatch Repair-Proficient Metastatic Colorectal Cancer: KEYNOTE-651 Cohorts B and D. Clinical Colorectal Cancer 2024, 23: 118-127.e6. PMID: 38762348, DOI: 10.1016/j.clcc.2024.03.001.Peer-Reviewed Original ResearchCitationsAltmetricConceptsMetastatic colorectal cancerObjective response rateCohort BCohort DAdverse eventsColorectal cancerT-cell-inflamed gene expression profileInvestigator-assessed objective response ratePD-L1 combined positive scoreTreatment-related adverse eventsResponse rateCombined positive scoreDose-limiting toxicityMedian follow-upTumor mutational burdenDecreased neutrophil countPrimary end pointMismatch repair-proficientStandard of careBiomarker analysisMethods PatientsRECIST v1.1PD-L1HER2 expressionMutational burdenSystemic Therapy for Advanced Hepatocellular Carcinoma: ASCO Guideline Update
Gordan J, Kennedy E, Abou-Alfa G, Beal E, Finn R, Gade T, Goff L, Gupta S, Guy J, Hoang H, Iyer R, Jaiyesimi I, Jhawer M, Karippot A, Kaseb A, Kelley R, Kortmansky J, Leaf A, Remak W, Sohal D, Taddei T, Wilson Woods A, Yarchoan M, Rose M. Systemic Therapy for Advanced Hepatocellular Carcinoma: ASCO Guideline Update. Journal Of Clinical Oncology 2024, 42: 1830-1850. PMID: 38502889, DOI: 10.1200/jco.23.02745.Peer-Reviewed Original ResearchCitationsAltmetricConceptsTyrosine kinase inhibitorsAdvanced hepatocellular carcinomaSecond-line therapyFirst-line treatmentRandomized controlled trialsHepatocellular carcinomaSystemic therapyFirst-lineChild-Pugh class A liver diseaseEastern Cooperative Oncology Group performance status 0Child-Pugh class A patientsSecond-line therapy optionsFirst-line settingPerformance status 0Third-line therapyFirst-line therapyClass A patientsEvidence-based guidelinesTolerated sorafenibStatus 0A patientsMechanism of actionTherapy optionsClinical decision-makingGuideline update
2023
NCI10066: a Phase 1/2 study of olaparib in combination with ramucirumab in previously treated metastatic gastric and gastroesophageal junction adenocarcinoma
Cecchini M, Cleary J, Shyr Y, Chao J, Uboha N, Cho M, Shields A, Pant S, Goff L, Spencer K, Kim E, Stein S, Kortmansky J, Canosa S, Sklar J, Swisher E, Radke M, Ivy P, Boerner S, Durecki D, Hsu C, LoRusso P, Lacy J. NCI10066: a Phase 1/2 study of olaparib in combination with ramucirumab in previously treated metastatic gastric and gastroesophageal junction adenocarcinoma. British Journal Of Cancer 2023, 130: 476-482. PMID: 38135713, PMCID: PMC10844282, DOI: 10.1038/s41416-023-02534-1.Peer-Reviewed Original ResearchCitationsAltmetricQuantitative DNA Repair Biomarkers and Immune Profiling for Temozolomide and Olaparib in Metastatic Colorectal Cancer
Cecchini M, Zhang J, Wei W, Sklar J, Lacy J, Zhong M, Kong Y, Zhao H, DiPalermo J, Devine L, Stein S, Kortmansky J, Johung K, Bindra R, LoRusso P, Schalper K. Quantitative DNA Repair Biomarkers and Immune Profiling for Temozolomide and Olaparib in Metastatic Colorectal Cancer. Cancer Research Communications 2023, 3: 1132-1139. PMID: 37387791, PMCID: PMC10305782, DOI: 10.1158/2767-9764.crc-23-0045.Peer-Reviewed Original ResearchCitationsMeSH Keywords and ConceptsConceptsWhole-exome sequencingMGMT protein expressionColorectal cancerStable diseaseQuantitative immunofluorescenceT cellsProtein expressionPromoter hypermethylationLow MGMT protein expressionPARP inhibitorsRadiographic tumor regressionMetastatic colorectal cancerAdvanced colorectal cancerPretreatment tumor biopsiesEffector T cellsTumor-infiltrating lymphocytesMGMT proteinDNA repair biomarkersBaseline CD8Eligible patientsIncreased CD8Methylguanine-DNA methyltransferaseObjective responseProgressive diseaseImmune markersPre-operative chemoradiotherapy with or without induction chemotherapy for operable locally-advanced esophageal cancer
Peters G, Talcott W, Peters N, Dhanasopan A, Lacy J, Cecchini M, Kortmansky J, Stein S, Lattanzi S, Park H, Boffa D, Johung K, Jethwa K. Pre-operative chemoradiotherapy with or without induction chemotherapy for operable locally-advanced esophageal cancer. Journal Of Gastrointestinal Oncology 2023, 14: 1181-1192. PMID: 37435226, PMCID: PMC10331751, DOI: 10.21037/jgo-22-1005.Peer-Reviewed Original ResearchCitationsAltmetricConceptsProgression-free survivalMedian progression-free survivalOverall survivalIC-CRTInduction chemotherapySingle-institution retrospective cohort studyPre-operative chemoradiotherapyAdvanced esophageal cancerAdvanced esophageal carcinomaPathologic complete responseRetrospective cohort studyKaplan-Meier methodSubset of patientsProportional hazards regressionCycles of inductionAdenocarcinoma histologyCRT cohortCohort studyComplete responsePathologic responseTreatment cohortsDistant metastasisHazards regressionEsophageal cancerEsophageal carcinoma
Clinical Trials
Current Trials
A Phase 2 Trial to Evaluate the Safety and Efficacy of Combination Therapies in Patients With Advanced Upper Gastrointestinal Tract Malignancies (EDGE-Gastric)
HIC ID2000033245RoleSub InvestigatorPrimary Completion Date09/30/2025Recruiting ParticipantsPhase 1b/3 Global, Randomized, Controlled, Open-label Trial Comparing Treatment With RYZ101 to Standard of Care Therapy in Subjects With Inoperable, Advanced, SSTR+, Well-differentiated GEP-NETs That Have Progressed Following Prior 177Lu-SSA Therapy
HIC ID2000033374RoleSub InvestigatorPrimary Completion Date07/31/2025Recruiting ParticipantsPhase 2 Study of Pembrolizumab and Brentuximab Vedotin in Subjects With Relapsed/Refractory CD30 Positive T-cell Lymphoma
HIC ID2000029793RoleSub InvestigatorPrimary Completion Date04/30/2028Recruiting ParticipantsColon Adjuvant Chemotherapy Based on Evaluation of Residual Disease
HIC ID2000032928RolePrincipal InvestigatorPrimary Completion Date03/10/2029Recruiting ParticipantsParallel Phase III Randomized Trials for High Risk Prostate Cancer Evaluating De-Intensification for Lower Genomic Risk and Intensification of Concurrent Therapy for Higher Genomic Risk With Radiation (PREDICT-RT*)
HIC ID2000032279RoleSub InvestigatorPrimary Completion Date12/31/2033Recruiting Participants
Clinical Care
Overview
Clinical Specialties
Medical Oncology
Fact Sheets
Gastrointestinal Cancers
Learn More on Yale MedicineHyperthermic Intraperitoneal Chemotherapy (HIPEC)
Learn More on Yale MedicineColorectal Cancer
Learn More on Yale MedicineLiver Cancer
Learn More on Yale Medicine
Yale Medicine News
Are You a Patient?
View this doctor's clinical profile on the Yale Medicine website for information about the services we offer and making an appointment.
View Doctor ProfileNews & Links
News
Related Links
Get In Touch
Contacts
Locations
Patient Care Locations
Are You a Patient? View this doctor's clinical profile on the Yale Medicine website for information about the services we offer and making an appointment.